The World Health Organization (WHO) approved the emergency use of a COVID-19 vaccine developed by US pharmaceutical company Novavax yesterday (21st) local time.
According to the WHO, “according to (WHO’s own) evaluation and recommendations for (conditional sale) approval by the European Medicines Agency, we have placed this vaccine on the urgent use list”.
The WHO also explained that the vaccine must be administered in two doses and can be maintained stably at a refrigeration temperature of 2 to 8 ° C.
With this approval, the number of COVID-19 vaccines approved by the WHO for emergency use will increase to 10.
Earlier, on the 17th, the WHO approved the emergency use of the COVID-19 vaccine ‘CovoVax’ produced by the Cerum Institute of India with the approval of Novavax.
Once on the WHO emergency use list, it can be distributed through COVAX, an international project for the joint purchase and distribution of COVID-19 vaccines.